Walleye Trading
KNSA icon

Walleye Trading’s Kiniksa Pharmaceuticals KNSA Stock Holding History

Walleye Trading’s Portfolio KNSA Stock Details KNSA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-6,900
Closed -$96K – 5471
2021
Q2 		$96K Buy
+6,900
New +$105K ﹤0.01% 4395

Other funds holding KNSA

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.51B AUM 546.08% 1-Year Est. Return
HA
HHLR Advisors Grand Cayman, Cayman Islands $832M AUM 32.38% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Pictet Asset Management
Pictet Asset Management Carouge, Switzerland $105B AUM 38.07% 1-Year Est. Return
B
Braidwell Stamford, Connecticut $2.7B AUM 88.53% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Walleye Trading's KNSA Position: Q1 2024 in Review

Walleye Trading sold out of Kiniksa Pharmaceuticals (KNSA) in Q1 2024, closing a stake of 21,424 shares — an estimated $376K sold.

Walleye Trading first reported a position in KNSA in Q3 2022 and held it in 2 quarters. The position peaked at $376K in Q4 2023. 154 funds tracked by Wall St. Rank hold KNSA as of Q1 2024.

  • Walleye Trading reported no remaining Kiniksa Pharmaceuticals position as of Q1 2024 after selling out during the quarter.
  • Walleye Trading sold 21,424 Kiniksa Pharmaceuticals shares in Q1 2024, an estimated $376K.
  • Walleye Trading first reported a position in Kiniksa Pharmaceuticals in Q3 2022 and held it in 2 quarters.
  • Walleye Trading's Kiniksa Pharmaceuticals position peaked at $376K in Q4 2023.
  • 154 funds tracked by Wall St. Rank held Kiniksa Pharmaceuticals as of Q1 2024.

Based on Walleye Trading's 13F filing for Q1 2024, filed 15 May 2024.